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Abstract  
Background 
Arterial stiffness is an established and potentially modifiable risk factor for cardiovascular disease, associated 
with chronic kidney disease. There have been few studies to evaluate progression of arterial stiffness over time 
or factors that contribute to this, particularly in early chronic kidney disease. We therefore investigated arterial 
stiffness over 5 years in an elderly population with chronic kidney disease stage 3, cared for in primary care. 
Methods 
1741 persons with estimated GFR 30-59mL/min/1.73m2 underwent detailed clinical and biochemical assessment 
at baseline, year 1 and 5. Carotid to femoral pulse wave velocity (PWV) was measured to assess arterial stiffness 
using a Vicorder™ device.  
Results 
970 participants had PWV assessments at baseline and 5 years. PWV increased significantly by a mean of 1.1 
m/s (from 9.7±1.9 to 10.8±2.1m/s). Multivariable linear regression analysis identified the following independent 
determinants of ΔPWV at year 5: baseline age, diabetes status, baseline systolic and diastolic blood pressure 
(BP), baseline PWV, ΔPWV at one year, Δ systolic BP over 5 years and Δ serum bicarbonate over 5 years (R2=0.38 
for equation).  
Conclusions 
We observed a clinically significant increase in PWV over 5 years in a cohort with early chronic kidney disease 
despite reasonably well controlled hypertension. Measures of blood pressure were identified as the most 
important modifiable determinant of change in PWV suggesting that interventions to prevent arterial disease 
should focus on improved control of blood pressure, particularly in those who evidence an early increase in 
PWV. These hypotheses should now be tested in prospective trials. 
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Introduction  
Cardiovascular disease (CVD) is highly prevalent in persons with chronic kidney disease (CKD) and is the leading 
cause of death and comorbidity in this population(1). Arterial stiffness (AS) has been identified as an important 
risk factor for cardiovascular events (CVE) and all-cause mortality in advanced CKD (2, 3).   
AS is significantly increased in persons with advanced CKD due to a combination of endothelial dysfunction (4), 
structural alterations (including production of less distensible collagen fibres), accumulation of advanced 
glycation end-products (AGEs) and calcification associated with CKD mineral bone disease (CKD-MBD)(5) . AS 
has also been associated with traditional cardiovascular risk factors such as diabetes(6), aging(7), 
hypertension(8), smoking(9) and dyslipidaemia(10). However the prevalence, pathogenesis and clinical 
significance of AS is unclear in persons with early CKD (11). Some studies have reported an increase in AS and 
cardiovascular risk associated with early CKD (12, 13) and others have not (14, 15). Additionally, there have been 
few longitudinal studies to evaluate progression of AS over an appropriate time period, particularly in patients 
with modest reductions in GFR. This is important because the majority of persons with CKD fall into categories 
G1-3 and early intervention may help to prevent later CVE’s.  
Pulse wave velocity (PWV) has been recognised as the gold standard for measuring AS (16) and is a blood 
pressure (BP) independent risk factor for cardiovascular disease in general populations (17, 18). In a previous 
cross-sectional analysis, we reported that age, mean arterial BP and diabetes were independent determinants 
of higher PWV in persons with early CKD (11).  The aim of this study was to extend these observations and 
investigate the progression of AS over 5 years in the same community-based elderly population with CKD stage 
3, to identify factors that may promote AS as potential therapeutic targets. 
 
Study Population and Methods 
Participants and recruitment 
The design and baseline characteristics of the Renal Risk in Derby Study (RRID) have been previously described 
(11, 19). Participants who were aged 18 years or older and had estimated GFR 30-59mL/min/1.73m2 on 2 
occassions at least 90 days apart, were assessed at baseline with follow-up visits at years 1 and 5. By year 5, 247 
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participants had died, 240 remained in the study but could not have PWV measurements for technical reasons 
and 284 were lost to follow up. Thus 970 had PWV readings from baseline through to year 5 and are included in 
this analysis.  
 
Data collection 
At each visit a medical questionnaire was completed, BP, anthropomorphic measurements and blood taken as 
well as three consecutive early morning urine specimens provided for analysis. Participants did not eat cooked 
meat for 12 hours prior to having blood taken. Carotid to femoral pulse wave velocity was measured (16) using 
a Vicorder™ device (Skidmore Medical Ltd, Bristol, UK) which gives similar values of PWV to other gold standard 
devices (20) and measures simultaneous pressure waveforms by a volume displacement technique, using BP 
cuffs placed around the sites of interest. Readings were obtained after the participant was rested in a semi prone 
position at approximately 30o in order to reduce the risk of venous contamination of the arterial signal. 
Measurement of the distance between the supra-sternal notch and thigh cuff was done via the direct method 
using a metal tape-measure as recommended in the AHA Scientific statement on standardising research into AS 
(16). To eliminate the effect of abdominal obesity on the distance measurement, an imaginary line was drawn 
from the supra sternal notch to the right shoulder and the measurement to the thigh cuff was made along the 
side of the body. 
BP was measured after a minimum of 5 minutes of rest in the sitting position, using a single calibrated 
oscillometric device(11). Measurements were taken until three within 10% of each other were obtained and the 
mean of these three readings used in analysis. Mean Arterial Blood Pressure (MAP) was calculated as 1/3 the 
mean systolic BP plus 2/3 the mean diastolic BP. Obesity was defined as a Body Mass Index (BMI)30kg/m2 and 
central obesity was defined as a waist to hip ratio of 0.9 for men and 0.8 for women. 
 
For recruitment GFR values were estimated using the 4-variable MDRD equation, however after publication of 
the CKD-EPI equation (21), eGFR values were re-calculated and these values are reported in this analysis.  
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The study was approved by the Nottingham Research Ethics Committee 1 and participants provided written 
informed consent.  
 
Statistical analysis 
Continuous variables were described using mean and standard deviation (SD) or median and interquartile range 
(IQR). Groups were compared using a t-test or Mann Whitney for continuous variables and Chi-square test for 
categorical variables. In univariable analyses, Pearson’s or Spearman’s test was used to assess correlations 
depending on distribution. Independent determinants of ΔPWV from baseline to year 5 were identified using 
multivariable linear regression analysis, employing the enter method. Variables were selected for inclusion in 
the multivariable analysis based on statistically significant associations in the univariable analysis and biological 
plausibility (variables previously reported to be associated with cardiovascular disease). Chronological age and 
variables related to albuminuria were included on the basis of biological plausibility. Bivariate correlations were 
conducted between independent variables to check for collinearity but none was identified. The closest 
correlation was between  SBP at year 5 and  DBP at year 5 (r=0.66).  Three multivariable models were 
developed: Model 1 included baseline variables only; in Model 2 variables from year 1 assessments were added; 
in Model 3 variables from year 5 assessments were added. The adjusted R-squared value is reported as a 
measure of goodness-of-fit. Data completeness was >98% for all variables. Missing data were excluded from 
analysis. 
To further assess progression of AS, participants were divided into 4 sub-groups according to change in PWV 
from baseline to 5 years. The threshold of 10m/sec was used to define elevated PWV, in line with current 
recommendations (22). Group 1 (Low-Low, n=304) had a PWV <10m/sec at baseline and year 5; Group 2 (Low-
High, n=264) had a PWV <10m/sec at baseline but ≥10m/sec at year 5; Group 3 (High-High, n=347) had a PWV 
≥10m/sec at baseline and year 5 and Group 4 (High-Low, n=55) had a PWV ≥10m/sec at baseline and <10m/sec 
at year 5. SPSS version 24 was used for all analyses. P<0.05 was considered statistically significant. 
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Results 
Demographic and clinical variables at baseline, years 1 and 5 are shown in Table 1. The cohort was predominately 
white ethnicity (99%), 61% female and few had a diagnosis of diabetes (14%) or previous history of CVD (17%). 
Approximately half (51%) had ever smoked. The majority were diagnosed with hypertension (86%) but BP was 
relatively well controlled. Estimated GFR was mildly reduced in the majority and only 15% had albuminuria 
(UACR>3mg/mmol). Baseline data for excluded participants are summarised in Supplementary Table 1. 
PWV increased significantly over time, with a mean increase of 1.1±2.0m/s over 5 years. Mean systolic and 
diastolic BP increased but a relatively greater rise in systolic BP resulted in an increase in pulse pressure, also a 
recognised marker of AS. Mean eGFR decreased by only 1.4±11.0ml/min/1.73m2. There was a moderate 
increase in UACR but albuminuria remained mild in the majority. 
Univariable analysis revealed significant correlations between ΔPWV at year 5 and previously identified risk 
factors for CVD (Table 2). The strongest correlations observed were with change in BP (systolic and diastolic) 
over time, baseline PWV (a negative correlation), year 1 PWV (a positive correlation) and serum bicarbonate as 
well as changes in bicarbonate. PWV increased to a greater extent in persons with diabetes, and those with 
uncontrolled BP at baseline (Supplementary Table 2). A weak correlation was observed between ΔPWV and 
baseline eGFR as well as change in eGFR but there was no association with UACR. Treatment with a renin 
angiotensin aldosterone system inhibitor (RAASi) at baseline was not associated with ΔPWV over time but those 
receiving a RAASi at year 5 had a higher PWV than those who were not. 
Multivariable linear regression analyses identified independent determinants of ΔPWV at year 5 (Table 3, 
adjusted R2=0.38). Baseline variables included age, diabetes, systolic and diastolic BP and PWV. Follow-up 
variables included ΔPWV at one year, Δ systolic BP over 5 years and Δ serum bicarbonate over 5 years. Markers 
of kidney disease (eGFR or UACR) were not independent determinants of ΔPWV in this population. 
To further explore determinants of change in PWV we compared subgroups with normal (Groups 1 and 2) or 
high (Groups 3 and 4) PWV at baseline (Table 4). There were no significant differences between the groups at 
baseline with respect to sex, smoking history, history of CVE, treatment with a RAASi, diastolic BP, BMI, high 
sensitivity C Reactive Protein (hsCRP) or multiple biochemical variables. Those who had normal PWV at baseline 
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but evidenced a change to high PWV at year 5 (Group 2) were older, had lower baseline eGFR and greater 
reduction in eGFR, higher systolic BP and greater increase in systolic BP as well as a greater increase in UACR 
when compared to those with normal PWV at baseline and no significant increase over time (Group 1). Those 
who had a high PWV at baseline but evidenced a decrease to normal PWV at year 5 (Group 4) were younger, 
had higher eGFR at baseline and slightly higher serum calcium at baseline compared to those with high PWV at 
baseline and year 5 (Group 3).  
 
Discussion 
We observed a clinically and statistically significant increase in PWV over 5 years in this population of older 
persons with mild CKD. Additionally we found that older age, diabetes and higher baseline systolic and diastolic 
BP were independent risk factors for subsequent increase in PWV. Increase in systolic BP (and to a lesser extent, 
increase in serum bicarbonate) over time was also independently associated with increase in PWV.  Measures 
of BP were identified as the most important modifiable determinant of change in PWV suggesting that 
interventions to prevent arterial disease in CKD should focus on control of BP. Increase in PWV at year 1 
predicted a further increase at year 5 implying that annual monitoring of PWV may be useful to identify persons 
at higher risk of further increase for more intensive treatment. 
Previous prospective cohort studies have concluded that an increase in PWV by 1 m/sec is associated with a 
significant increase in cardiovascular mortality and morbidity (23, 24) with an odds ratio for all-cause mortality 
of 1.39 (95% CI 1.19 to 1.62) in patients with end stage kidney disease (ESKD). Importantly we have observed 
this magnitude of increase in PWV in a cohort with much earlier stage CKD and limited CKD progression (25). 
There is a lack of published data on change in PWV over time in persons with CKD. Previous prospective studies 
have been relatively short-term (26) or performed PWV measurements only at baseline (27, 28). In a large study 
of CKD stage 3 to 4, 2933 participants had PWV assessments at 2 and 4 years however, change in PWV over time 
was not reported (29). Another study of 255 participants with early CKD followed up for 4 years reported no 
change in PWV at group level but it was unclear on how often PWV was measured (30). One relatively small 
study conducted by Tholen et al (31) showed an increase in PWV of 1.1m/sec over one year in 70 persons with 
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CKD stage 3 or 4. This suggests a substantially more rapid increase to that observed in our cohort, as we did not 
observe a rise in PWV after one year. One reason for the accelerated rise may have been the higher prevalence 
of diabetes (64% versus 14% in our study ), which we identified as an independent risk factor for PWV increase.  
A further consideration is that, due to the longitudinal nature of our study, some of the higher risk participants 
did not complete 5 years of follow-up and we may therefore have underestimated the increase in PWV. For 
example 294 persons with diabetes entered at baseline, but only 133 completed year 5 visits. Supplementary 
Table 1 confirms that those who did not have PWV measured at year 5 had a higher cardiovascular risk profile 
at baseline than those included (multiple variables) and therefore would probably have evidenced a greater 
increase in PWV.  Tholen et al. were unable to perform multivariable analysis due to small sample size but did 
observe that age, systolic BP, diabetes and PWV at baseline were significantly higher in persons with progressive 
rather than stable PWV (33), factors that we found to be significant independent determinants in our analysis.  
We identified measures of BP as important risk factors for PWV increase in early CKD. Previous cross-sectional 
studies have similarly reported that BP is strongly associated with PWV (32) but our prospective longitudinal 
study provides stronger evidence of a causal relationship. It is proposed that elevated BP stimulates production 
of less distensible collagen fibres in arterial walls, resulting in progressively stiffer arteries (33). Nevertheless, 
the interaction between AS and BP in the setting of CKD is complex. In the context of ESKD requiring 
haemodialysis (HD) there is debate on whether BP influences PWV or vice versa (34, 35) and there are other 
factors present to confound the relationship between BP and PWV, such as the effect of fluid gain and 
removal(35), endothelial dysfunction, accumulation of AGEs (36) and CKD-MBD. However, in persons with CKD 
stage 3 these issues are less relevant and we found no independent associations between PWV and markers of 
kidney function or CKD-MBD. Studies conducted in general population cohorts have reported findings similar to 
ours.  One longitudinal study of 943 participants in the general population concluded that systolic BP and AS 
interact in a vicious cycle (37) and another reported that PWV increased at a greater rate in persons with 
uncontrolled hypertension compared with controlled hypertension and normotensive participants (38).  We 
observed progression of AS, even with moderately good baseline BP control (mean of 133/74 mmHg), though 
only 60.2% of participants achieved the KDIGO BP guideline targets(39). Additionally, a small but significant 
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increase in BP was observed over 5 years. Both systolic and diastolic BP at baseline as well as change in systolic 
BP over 5 years were independent determinants of an increase in PWV over 5 years. Moreover, change in PWV 
at year 1 independently predicted change in PWV at year 5. Our findings suggest that improved control of 
hypertension in early CKD may limit AS over time, lowering rates of subsequent CVE and mortality. Additionally, 
annual monitoring of PWV may identify persons at risk for further rise in PWV who may benefit from more 
intensive antihypertensive therapy. These hypotheses should now be tested in prospective trials. The benefit of 
improved BP control has been reported in a subgroup analysis of 2646 participants with CKD from the SPRINT 
trial. Participants randomized to achieve a systolic BP of <120mmHg had lower rates of major CVE and all-cause 
mortality over 3.3 years compared to those who were targeted to achieve <140mmHg (40) but unfortunately AS 
was not assessed.  
We also found age and diabetes to be independent determinants of change in PWV. Age has previously been 
identified as a determinant of AS and vascular ageing is a known risk factor for CVE and mortality. The best 
reported changes with ageing are remodelling (luminal enlargement with wall thickening) and arteriosclerosis 
(reduction of elastic properties at the level of large elastic arteries) (41). Chue et al. reported reduced thoracic 
aorta distensibility in patients with early stage CKD mimicking that seen as a result of ageing (42). Diabetes is 
also a well-documented independent predictor of cardiovascular risk and mortality and may enhance AS through 
increased inflammation and deposition of AGEs (43, 44) that provoke structural changes in the arterial wall (45) 
and the generation of reactive oxygen species that deactivate nitric oxide resulting in endothelial dysfunction 
(46).  
We observed that an increase in serum bicarbonate over time was also an independent determinant of 
increasing PWV. This unexpected finding likely reflects increased use of diuretics in those with more resistant 
hypertension, though we did not have follow-up data on diuretic use to investigate this. On the other hand, 
evidence from animal models of CKD suggests that metabolic acidosis may actually protect against arterial 
calcification (47). One cross-sectional analysis from a community based study of 1698 people did not find an 
association between serum bicarbonate concentrations and AS assessed by PWV (48) though only 11% of the 
cohort had an eGFR <60mL/min/1.73m2.  
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Interestingly, other factors that have been associated with changes in AS in more advanced stages of kidney 
disease were not independent determinants in our study population. Markers of CKD such as eGFR and 
albuminuria were either not significant at all or were associated with change in PWV only in the univariable 
analysis. This suggests that markers of CKD are not strong determinants of AS in earlier stages of CKD and that 
cardiovascular risk in this group is associated with other, perhaps more traditional risk factors. Another 
longitudinal study of 181 people with early CKD in the Framingham Heart Study (28) observed that higher AS 
measures were not associated with CKD and or albuminuria in multivariable analysis. In a further longitudinal 
study of 913 participants (100 with CKD stage 3) with a mean age of 63 years and baseline eGFR of 83.7±18 
mL/min/1.73m2 , lower eGFR and rapid decline in kidney function did not correlate with AS (27). Markers of 
inflammation also did not appear to be independent determinants in our analysis. In the largest cohort of 2,933 
participants with early CKD investigating both cross sectional and longitudinal associations between AS and 
inflammation, the investigators found significant correlations between AS and inflammatory markers at 
baseline. However longitudinal analysis over 4 years found no associations between inflammatory markers at 
baseline (apart from serum albumin) and change in PWV over time (29). 
Baseline PWV was an independent determinant of ΔPWV over 5 years with an inverse relationship. This may be 
due to the statistical phenomenon of regression to the mean. We therefore included baseline PWV in our 
multivariable model to correct for this.  Another study of 255 mainly male veterans followed up over 4 years, 
with a baseline mean age of 69.4±9.9 years and a mean eGFR of 44 ml/min/1.73m2, also noted an inverse 
relationship (30). In contrast, change in PWV over the first year was independently positively associated with 
change in PWV over 5 years, implying that annual monitoring may detect persons at risk of a progressive increase 
in PWV over a longer period.   
 
Our data should be interpreted in the light of some limitations. As described, PWV was measured with a 
Vicorder™ device whereas many other studies have used aplanation tonometry devices such as the SphymoCor™ 
on Complior™. Nevertheless, measurements using Vicorder™ have been shown to correlate well with 
SphygmoCor™ and are reproducible (20). Second, 44% of the original cohort of 1741 participants did not 
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complete the Year 5 visit and were not included in this analysis. As shown in Supplementary Table 1, excluded 
participants were older, had lower eGFR, more diabetes and higher systolic BP and would therefore probably 
have evidenced greater increases in PWV.  Finally, 99% of participants were of white ethnicity and our results 
may therefore not be applicable to more ethnically diverse populations. 
In conclusion, we observed a clinically significant increase in PWV over 5 years in a cohort of predominantly 
older people with CKD stage 3, and reasonably well controlled BP. Systolic and diastolic BP at baseline as well as 
change in systolic BP over 5 years were identified as the most important modifiable determinants of change in 
PWV and an increase in PWV at 1 year predicted a further rise at 5 years. Our findings suggest that interventions 
to prevent arterial disease should focus on improving control of BP in this population, particularly those who 
evidence an early increase in PWV. These hypotheses should now be tested in prospective trials. 
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Table 1. Clinical characteristics of participants with ΔPWV at year 5 (n = 970) 
  Baseline Year 1 Year 5 
P value  
Baseline vs Year 5 
          
Age (years)  71(65-76)  72(66-77)  76(70-82) <0.0001 
eGFR CKD EPI 
(mL/min/1.73m2) 55.7±11.6 55±12.8 54.3±15.1 <0.0001 
Systolic BP (mmHg) 133±17 130±16 139±20 <0.0001 
Diastolic BP (mmHg) 74±11 71±10 75±11 <0.0001 
PWV (m/sec) 9.7±1.9 9.5±1.8 10.8±2.1 <0.0001 
PP (mmHg) 59±15 58±15 64±19 <0.0001 
MAP (mmHg) 94±11 91±10 97±12 <0.0001 
UACR (mg/mmol) 0.23 (0.00-1.10) 0.50(0.2-1.60) 0.67(0.00-3.20) <0.0001 
Haemoglobin(g/dL) 13.4±1.3 13.4±1.3 13.1±1.4 <0.0001 
Corrected Calcium (mmol/L) 2.38±0.1 2.39±0.09 2.44±0.09 <0.0001 
Phosphate (mmol/L) 1.11(0.98-1.22) 1.09(0.95-1.22) 1.07(0.95-1.18) <0.0001 
Bicarbonate (mmol/L) 25.5±2.5 25.3±2.6 25.1±2.6 <0.0001 
Albumin (mmol/L) 41(39-43) 40(38-42) 37(35-39) <0.0001 
Total Protein (g/L) 74(71-77) 71(68-74) 70(68-73) <0.0001 
Total Cholesterol (mmol/L) 4.7(3.9-5.7) 4.5(3.8-5.4) 4.45(3.7-5.4) <0.0001 
HDL (mmol/L) 1.39(1.13-1.70) 1.40(1.19-1.73) 1.46(1.20-1.80) <0.0001 
Uric Acid (µmol/L) 380±88 382±88 371±87 <0.0001 
Obese 360(37) 372(38) 346(36) <0.0001 
Waist to Hip Ratio 0.9±0.09 0.9±0.09 0.9±0.08 0.706 
BMI (kg/m2) 28.4(25.6-31.8) 28.3(25.9-31.9) 28.3(25.6-31.8) 0.164 
     
Data are ±SD or median (IQR), PWV=Pulse Wave Velocity, HDL=High Density Lipo-protein, BMI=Body Mass Index, 
PP=Pulse Pressure, MAP=Mean Arterial Pressure 
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Table 2. Significant correlations with ΔPWV, baseline to year 5. 
  r p value 
      
Age at Baseline (years) 0.056 0.08 
Baseline SBP (mmHg) -0.097 0.003 
Baseline DBP (mmHg) -0.085 0.008 
Delta SBP Baseline to Y1 (mmHg) 0.183 <0.0001 
Delta DBP Baseline to Y1 (mmHg) 0.146 <0.0001 
Delta SBP Baseline to Y5 (mmHg) 0.235 <0.0001 
Delta DBP Baseline to Y5 (mmHg) 0.193 <0.0001 
Baseline PWV (m/sec) -0.431 <0.0001 
Delta PWV Baseline to Y1 (m/sec) 0.52 <0.0001 
Baseline Bicarbonate (mmol/L) -0.058 0.07 
Delta Bicarbonate Baseline to Y1 (mmol/L) 0.128 <0.0001 
Delta Bicarbonate Baseline to Y5 (mmol/L) 0.116 <0.0001 
Baseline Total Protein (g/L) -0.096 0.003 
Delta Total Protein Baseline to Y5 (g/L) 0.124 <0.0001 
Baseline eGFR CKD-EPI (mL/min/1.73m2) -0.072 0.026 
Delta eGFR CKD-EPI Baseline to Y5 (mL/min/1.73m2) 0.065 0.043 
Baseline hsCRP ‡ (mg/L)* -0.006 0.86 
Baseline BMI (kg/m2)* -0.023 0.47 
Year 1 BMI (kg/m2)* -0.028 0.39 
Year 5 BMI (kg/m2)* -0.012 0.72 
Delta BMI Baseline to Y5 (kg/m2) 0.015 0.65 
Baseline UACR ‡ (mg/mmol)* -0.025 0.44 
Delta UACR Baseline to Y1 (mg/mmol)* -0.005 0.88 
Delta UACR Baseline to Y5 (mg/mmol)* 0.005 0.88 
*Spearman correlation co-efficient     
‡ log transformed data     
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Table 3. Independent determinants of increase in PWV over 5 years. 
 Model 1 Model 2 Model 3 
 
(Baseline variables) (plus Y1 variables) (plus Y5 variables) 
 
Adjusted R2=0.26 Adjusted R2=0.34 Adjusted R2=0.38 
  ᵦ p value ᵦ p value ᵦ p value 
Baseline variables       
PWV at Baseline (m/sec) -0.574 <0.0001 -0.336 <0.0001 -0.338 <0.0001 
Age at Baseline (yrs)  0.267 <0.0001 0.168 <0.0001 0.165 <0.0001 
Diabetes Mellitus 0.104 <0.0001 0.089 0.002 0.099 <0.0001 
Systolic BP at Baseline (mmHg) 0.037 0.30 0.042 0.27 0.089 0.022 
Diastolic BP at Baseline(mmHg) 0.029 0.42 0.057 0.14 0.089 0.025 
eGFR CKD-EPI at Baseline (mL/min/1.73m2) -0.050 0.12 -0.050 0.10 -0.037 0.23 
UACR at Baseline (mg/mmol) ‡ -0.033 0.26 -0.038 0.17 -0.038 0.17 
Bicarbonate at Baseline (mmol/L) -0.039 0.18 0.021 0.51 0.045 0.19 
Total Protein at Baseline (g/L) -0.036 0.21 -0.032 0.25 0.015 0.66 
On RAASi at Baseline -0.036 0.21 -0.030 0.28 -0.005 0.87 
Year 1 variables       
Δ Systolic BP Base to Y1 (mmHg)   0.102 0.009 0.04 0.32 
Δ Diastolic BP Base to Y1 (mmHg)   0.015 0.71 0.012 0.77 
Δ PWV Baseline to Y1 (m/sec)   0.316 <0.0001 0.319 <0.0001 
Δ Bicarbonate Baseline to Y1 (mmol/L)   0.079 0.01 0.049 0.14 
Year 5 variables       
Δ Systolic BP Baseline to Y5(mmHg)     0.167 <0.0001 
Δ Diastolic BP Baseline to Y5(mmHg)     0.043 0.31 
Δ eGFR CKD-EPI Baseline to Y5 (mL/min/1.73m2)     -0.029 0.28 
Δ UACR Baseline to Y5 (mg/mmol) ‡     0.02 0.46 
Δ Bicarbonate Baseline to Y5 (mmol/L)     0.069 0.039 
Δ Total Protein Baseline to Y5 (g/L)     0.046 0.18 
On RAASi at Year 5     -0.036 0.26 
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PWV=Pulse Wave Velocity; eGFR= estimated Glomerular Filtration Rate using the CKD-EPI Formula; RAASi=Renin Angiotensin Aldosterone System inhibitor; 
UACR= Urinary Albumin to Creatinine Ratio 
‡=log transformed data 
  
21 
 
Table 4. Subgroup analysis: Demographic and clinical characteristics in 4 groups defined by PWV measurement at baseline and change over 5 years. 
  
Group 1 (Low-Low) 
n=304 
Group 2 (Low-High) 
n=264 
P value 
G1 vs G2 
Group 3 (High-High) 
n=347 
Group 4 (High-Low) 
n=55 
P value  
G3 vs G4 
              
Age (Years) at Baseline 65(59-70) 72(67-76) <0.0001 75(70-79) 71(65-76) <0.0001 
Diabetes 30(10) 35(13) 0.21 63(18) 5(9) 0.1 
Male Gender 88(29) 98(37) 0.38 166(48) 23(42) 0.41 
Ever Smoked @ Baseline 151(50) 132(50) 0.94 184(53) 27(49) 0.59 
Previous History of CVE @ Baseline 49(16) 41(16) 0.85 70(20) 8(15) 0.33 
eGFR CKD-EPI (mL/min/1.73m2)@Baseline 58.2±11.4 54.8±11 <0.0001 53.8± 57.7±13.1 0.023 
eGFR CKD-EPI (mL/min/1.73m2) @Y5 57.6±15.4 53.6±13.8 0.001 52±15.1 54.8±17.4 0.2 
Δ eGFR CKD-EPI (mL/min/1.73m2) Baseline to Y5 -0.56±11 -1.24±11 0.46 -1.84±11 -2.88±11 0.5 
SBP (mmHg)@ Baseline 126±16 130±15 0.005 140±17 139±16 0.59 
SBP (mmHg)@ Y5 131(119-143) 142(129-153) <0.0001 141(128-155) 136(125-150) 0.12 
Δ SBP(mmHg) Baseline to Y5 6±19 13±21 <0.0001 3±23 -0.6±17 0.29 
DBP (mmHg)@ Baseline 74±11 72±10 0.14 75±11 77±11 0.18 
DBP (mmHg)@ Y5 76±10 76±11 0.5 74±11 75±11 0.62 
Δ DBP (mmHg)Baseline to Y5 2±10 4±10 0.07 -0.7±12 -2±11 0.43 
On a RAASi @ Baseline 187(62) 167(63) 0.67 222(64) 35(64) 0.96 
On a RAASi @ Y5 190(63) 160(61) 0.64 217(63) 39(71) 0.23 
PWV (m/sec)@ Baseline 8.1(7.4-8.9) 8.9(8.3-9.5) <0.0001 11.1(10.4-12.2) 10.8(10.2-11.5) 0.016 
PWV (m/sec)@ Y1 8.0(7.4-9.0) 9.3(8.5-10.1) <0.0001 10.7(9.6-11.6) 9.7(8.5-10.4) <0.0001 
PWV (m/sec)@ Y5 8.8(8.2-9.5) 11.1(10.6-12.1) <0.0001 12.2(11.1-13.3) 9.1(8.1-9.6) <0.0001 
Δ PWV (m/sec)@ Baseline to Y5 0.6(0-1.3) 2.5(1.7-3.5) <0.0001 0.7(-0.3-2.0) -2.1(-3.2 to-1.2) <0.0001 
PP (mmHg) @ Baseline 50(42-59) 57(49-66) <0.0001 64(56-74) 61(52-70) 0.11 
PP (mmHg) @ Y5 53(43-66) 64(53-77) <0.0001 67(53-81) 58(51-75) 0.021 
Hb (g/dL) @ Baseline 13.5±1.4 13.3±1.3 0.19 13.4±1.3 13.3±1.2 0.82 
Corrected Calcium (mmol/L) @ Baseline 2.37(2.32-2.43) 2.37(2.32-2.43) 0.88 2.37(2.31-2.43) 2.4(2.34-2.45) 0.028 
Phosphate (mmol/L) @ Baseline 1.11±0.17 1.11±0.18 0.8 1.09±0.18 1.13±0.17 0.07 
Albumin (mmol/L) @ Baseline 41(39-43) 41(39-43) 0.83 41(39-43) 41(39-42) 0.21 
Total Protein (g/L)@ Baseline 74(71-77) 74(71-77) 0.44 75(72-78) 75(73-78) 0.28 
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Total Protein (g/L)@ Y5 70(68-73) 70(68-73) 0.69 71(68-73) 71(68-73) 0.76 
Total Cholesterol (mmol/L)@ Baseline 4.8(4-5.7) 4.7(3.9-5.8) 0.64 4.6(3.9-5.6) 5.1(4-6.2) 0.15 
Uric Acid (µmol/L) @ Baseline 367(310-434) 379 (320-442) 0.19 381(317-444) 380(321-435) 0.83 
Uric Acid (µmol/L) @ Y5 371(312-427) 362(305-419) 0.36 371(313-424) 370(316-420) 0.94 
Bicarbonate (mmol/L) @ Baseline 26(24-27) 26(24-27) 0.35 26(24-27) 25(24-27) 0.84 
Bicarbonate (mmol/L) @ Y5 25.1±2.7 25.3±2.6 0.62 25±2.5 24.8±2.6 0.45 
Δ Bicarbonate (mmol/L) @ Baseline to Y5 -0.5±3  -0.1±2.9 0.14 -0.4±3 -1.0±2.5 0.21 
hsCRP (mg/L)* @ Baseline 0.32(0.04-0.59) 0.32(0.01-0.61) 0.74 0.32(0.03-0.64) 0.34(0.05-0.58) 0.99 
UACR (mg/mmol) @ Baseline 0.17(0.00-0.70) 0.23(0.00-1.5) 0.07 0.33(0.00-1.47) 0.20(0.00-1.25) 0.51 
UACR (mg/mmol) @ Y5 0.30(0.00-1.6) 0.53(0.00-3.37) 0.028 1.17(0.20-4.87) 0.80(0.07-3.4) 0.5 
BMI (kg/m2) @ Baseline 29.4(25.9-32.9) 28.4(25.6-32.1) 0.27 27.9(25.6-30.3) 28.3(24.2-32.1) 0.86 
BMI (kg/m2) @ Y5 29.0(25.9-32.6) 28.3(26-32.2) 0.35 27.6(25.3-30.6) 27.4(24.6-31.8) 0.86 
              
All data are Mean±SD, Median(IQR) or 
Number(%)       
CVE=Cardiovascular Event, eGFR=estimated Glomerular Filtration Rate using the CKD-EPI formula, SBP=Systolic Blood Pressure, DBP= Diastolic Blood Pressure  
RAASi=Renin Angiotensin Aldosterone System inhibitor, PWV= Pulse Wave Velocity, PP= Pulse Pressure, Hb=Haemoglobin, hsCRP=high sensitivity C-Reactive Protein 
UACR= Urinary Albumin to Creatinine Ratio, BMI=Body Mass Index      
Group 1: (Low-Low) = aPWV<10m/sec at Baseline and Year 5, Group 2: (Low-High) = aPWV<10m/sec at Baseline but ≥10m/sec at Y5   
Group 3: (High-High) = aPWV≥10m/sec at Baseline and Year 5, Group 4: (High-Low) = aPWV≥10m/sec at Baseline but<10m/sec at Year 5   
* Log- transformed data, **Gender Specific             
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Supplementary Table 1. RRID study Cohort (n=1741): Comparison of Baseline Characteristics in participants who had a Delta PWV Baseline to Y5, to those 
without. 
 
  Those with a Delta PWV Baseline to Y5 (n=970) n Without Delta PWV(n=771*) n P value 
            
Age (yrs) 71(65-76) 970 78(72-82) 771 <0.0001 
Male Gender 375(39) 970 314(41) 771 0.381 
Diabetes 133(14) 970 161(21) 771 <0.0001 
Ethnicity White 956(99) 970 742(96) 771 0.002 
Qualifications None 477(49) 970 476(62) 771 <0.0001 
Ever Smoked 494(51) 970 453(59) 771 0.001 
Previous CVE 143(15) 970 150(20) 770 <0.0001 
eGFR CKD-EPI (mL/min/1.73m2) 55.7±11.6 970 50.9±11.5 771 <0.0001 
SBP (mmHg) 133±17 970 136±20 771 0.003 
DBP (mmHg) 74±11 970 71±11 771 <0.0001 
SBP≥140 mmHg 310(32) 970 294(38) 771 0.007 
BP≥140/90 mmHg 326(34) 970 298(39) 771 0.029 
PP (mmHg) 58(48-68) 970 63(52-75) 771 <0.0001 
MAP (mmHg) 94±11 970 93±12 771 0.125 
PWV (m/sec) 9.7±1.9 970 10.2±2.0 747 <0.0001 
On Antihypertensive Therapy 776(80) 970 650(84) 771 0.02 
On ≥2 Antihypertensive Agents 442(46) 970 369(48) 771 0.341 
On RAASi 611(63) 970 512(66) 771 0.139 
On NSAID 80(8) 970 66(9) 771 0.815 
UACR (mg/mmol) 0.23(0.00-1.90) 969 0.53(0.00-1.90) 769 <0.0001 
Albuminuria 143(15) 970 150(20) 770 0.009 
Hb (g/dL) 13.4±1.3 968 13±1.5 768 <0.0001 
Corrected Calcium (mmol/L) 2.37(2.32-2.43) 963 2.37(2.31-2.43) 767 0.23 
Phospate (mmol/L) 1.10±0.18 954 1.11±0.18 755 0.327 
Albumin (mmol/L) 41(38-43) 967 40(39-43) 771 <0.0001 
Total Protein (g/L) 74±5 967 74±5 765 0.149 
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Total Cholesterol (mmol/L) 4.7(3.8-5.3) 965 4.5(3.9-5.7) 767 <0.0001 
HDL (mmol/L) 1.39(1.13-1.70) 965 1.40(1.12-1.72) 767 0.658 
Uric Acid (µmol/L)  380±88 964 390±95 767 0.024 
Bicarbonate (mmol/L) 25.5±2.5 960 25.5±2.9 762 0.625 
Waist to Hip Ratio 0.9±0.09 970 0.92±0.09 770 <0.0001 
BMI (kg/m2) 28.4(25.6-31.8) 970 28.8(25.7-31.8) 770 0.583 
Central Obesity 839(87) 970 697(90) 770 0.01 
Obese (BMI≥30) 360(37) 970 289(38) 770 0.858 
Morbid Obesity (BMI≥40) 28(3) 970 31(4) 770 0.15 
            
* By year 5: 247 participants had died, 240 remained in the study but could not have PWV measurements and 284 were lost to follow up. 
 
  
25 
 
Supplementary Table 2. ΔPWV baseline to year 5 in potentially significant subgroups. 
  Yes No p value 
        
Male 1.1±1.9 1.1±2.1 0.66 
Diabetes 1.4±1.9 1.0±2.0 0.046 
Ethnicity White 1.1±2.0 1.8±3.5 0.45 
Ever smoked @ Baseline 1.1±1.9 1.1±2.1 0.94 
No Educational Qualifications @Baseline 1.1±1.9 1.1±2.1 0.85 
Previous CVE @ Baseline 1.1±2.2 1.1±2.0 0.99 
Systolic BP≥140 (mmHg) @ Baseline 0.8±2.0 1.2±2.0 0.007 
Diastolic BP≥90 (mmHg)@ Baseline 0.7±1.7 1.1±2.0 0.07 
BP≥140/90 (mmHg) @ Baseline 0.9±2.0 1.2±2.0 0.01 
On RAASi @ Baseline 1.1±2.0 1.1±2.1 0.9 
On RAASi @ Year 5 1.0±2.0 1.3±2.0 0.033 
On NSAID @ Baseline 1.0±1.9 1.1±2.0 0.53 
On NSAID at Y5 1.1±2.0 1.1±2.3 0.85 
        
RAASi=Renin Angiotensin Aldosterone System inhibitor, NSAID= Non-Steroidal Anti-inflammatory Drug 
   
 
 
